{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T13:39:36Z","timestamp":1790602776542,"version":"4.1.0"},"reference-count":6,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s10147-025-02939-3","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T11:27:27Z","timestamp":1765798047000},"page":"225-226","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; encorafenib for colorectal cancer, daratumumab for multiple myeloma, repotrectinib for NTRK-fusion positive solid tumors, and venetoclax for leukemia"],"prefix":"10.1007","volume":"31","author":[{"given":"Noriomi","family":"Matsumura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Mandai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,15]]},"reference":[{"key":"2939_CR1","unstructured":"Pharmaceuticals and medical devices agency (2025) List of approved drugs (in Japanese) https:\/\/www.pmda.go.jp\/review-services\/drug-reviews\/review-information\/p-drugs\/0010.html Accessed on November 30, 2025"},{"key":"2939_CR2","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1038\/s41591-024-03443-3","volume":"31","author":"S Kopetz","year":"2025","unstructured":"Kopetz S, Yoshino T, Van Cutsem E et al (2025) Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial. Nat Med 31:901\u2013908. https:\/\/doi.org\/10.1038\/s41591-024-03443-3","journal-title":"Nat Med"},{"key":"2939_CR3","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1056\/NEJMoa2409029","volume":"392","author":"MA Dimopoulos","year":"2025","unstructured":"Dimopoulos MA, Voorhees PM, Schjesvold F et al (2025) Daratumumab or active monitoring for high-risk smoldering multiple myeloma. N Engl J Med 392:1777\u20131788. https:\/\/doi.org\/10.1056\/NEJMoa2409029","journal-title":"N Engl J Med"},{"key":"2939_CR4","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","volume":"380","author":"K Fischer","year":"2019","unstructured":"Fischer K, Al-Sawaf O, Bahlo J et al (2019) Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med 380:2225\u20132236. https:\/\/doi.org\/10.1056\/NEJMoa1815281","journal-title":"N Engl J Med"},{"key":"2939_CR5","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200006","volume":"1","author":"AP Kater","year":"2022","unstructured":"Kater AP, Owen C, Moreno C et al (2022) Fixed-duration ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities. NEJM Evid 1:EVIDoa2200006. https:\/\/doi.org\/10.1056\/EVIDoa2200006","journal-title":"NEJM Evid"},{"issue":"(12_Supplement)","key":"2939_CR6","doi-asserted-by":"publisher","first-page":"02","DOI":"10.1158\/1535-7163.TARG-21-P02-01","volume":"20","author":"B Besse","year":"2021","unstructured":"Besse B, Baik C, Springfeld C et al (2021) Repotrectinib in patients with NTRK fusion-positive advanced solid tumors: update from the registrational phase 2 TRIDENT-1 trial. Mol Cancer Ther 20((12_Supplement)):02\u201301. https:\/\/doi.org\/10.1158\/1535-7163.TARG-21-P02-01","journal-title":"Mol Cancer Ther"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02939-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-025-02939-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02939-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T04:07:45Z","timestamp":1769486865000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-025-02939-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,15]]},"references-count":6,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["2939"],"URL":"https:\/\/doi.org\/10.1007\/s10147-025-02939-3","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,15]]},"assertion":[{"value":"15 December 2025","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}